7,448.25

+46.25

+0.62%

51,876.00

+491.00

+0.96%

27,248.75

+163.50

+0.60%

Russell 2000 Futures

2,794.00

+33.50

+1.21%

4.8590

+0.0220

+0.45%

23.52

-2.12

-8.25%

4,124.00

+49.10

+1.20%

74,727.14

-1,141.18

-1.50%

Crude Oil Dec 26

88.25

-2.58

-2.84%

US Private Equity

10,772.76

+11.83

+0.11%

Frankfurt - Delayed Quote EUR

Chugai Pharmaceutical Co., Ltd. (CUP.F)

40.07 +1.67 (+4.35%)

As of 9:55:01 AM GMT+1. Market Open.

Loading Chart for CUP.F

Chart Range Bar

Interval:

In partnership with ChartIQ

CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index

CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index

Chugai Pharmaceutical (TSE:4519) Stock Price Trails Strong Q3 Earnings

Chugai Pharmaceutical (TSE:4519) Stock Price Trails Strong Q3 Earnings

Chugai expects full-year results to beat forecast as drug exports and royalties gr

Chugai expects full-year results to beat forecast as drug exports and royalties gr

Chugai Pharmaceutical (TSE:4519) Stock May Be Cheap On Cash Flow

Chugai Pharmaceutical (TSE:4519) Stock May Be Cheap On Cash Flow

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Will Regaining Emugrobart Rights and Refocusing on SMA Change Chugai Pharmaceutical's (TSE:4519) Narrative

Will Regaining Emugrobart Rights and Refocusing on SMA Change Chugai Pharmaceutical's (TSE:4519) Narrative

Oil Bills, Bond Yields, Tech Jitters Damp Asian Stock Markets

Oil Bills, Bond Yields, Tech Jitters Damp Asian Stock Markets

Chugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Own

Chugai Pharmaceutical And 2 Japanese AI Healthcare Stocks To Own

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors

Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight

Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight

3 Japanese AI Healthcare Stocks Investors May Want To Watch

3 Japanese AI Healthcare Stocks Investors May Want To Watch

Mobilize your Website

View Site in Mobile | Classic

Share by: